Quick Answer
enGene Therapeutics Inc. reported R&D Expense of $94.48 million for fiscal year 2025.
enGene Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $94.48M | +146.6% |
| 2024 | $38.31M | +132.8% |
| 2023 | $16.46M | +6.4% |
| 2022 | $15.47M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $22.25M | +11.4% | -1.4% |
| July 31, 2025 | $22.57M | +95.5% | +11.7% |
| April 30, 2025 | $20.21M | +105.1% | +1.2% |
| January 31, 2025 | $19.97M | +254.3% | +73.0% |
| July 31, 2024 | $11.55M | +196.1% | +17.2% |
| April 30, 2024 | $9.86M | +206.5% | +74.8% |
| January 31, 2024 | $5.64M | +53.6% | +44.5% |
| July 31, 2023 | $3.90M | — | +21.3% |
- enGene Therapeutics Inc. showed an increase of +146.6% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s r&d expense has grown by 510.8% (from $15.47 million to $94.48 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: